Introduction of temozolomide capsules

Temozolomide capsules (trade name: TEDA? ), a prescription drug, is developed by Merck (called Merck in the United States and Canada) and licensed for production. The indication is to treat the newly diagnosed glioblastoma multiforme. Temozolomide is a new oral alkylating agent anti-tumor drug with broad-spectrum anti-tumor activity, which can penetrate the blood-brain barrier and its bioavailability is close to 100%. Temozolomide can effectively treat newly diagnosed and recurrent glioblastoma and anaplastic astrocytoma, prolong the survival time of patients, and has good safety and tolerance. At present, the treatment mode of glioma is still multidisciplinary comprehensive treatment based on surgery, that is, surgery plus postoperative radiotherapy and chemotherapy, which is also the gold standard for glioma treatment. "Surgery-Gatimozolamide (Taidao? ) Concurrent chemoradiotherapy plus temozolomide (Taidao? "Adjuvant chemotherapy" is a new standard treatment mode recognized at home and abroad for the diagnosis of malignant glioma. "Too knife? It is the first-line drug to treat glioma in the world. 120 12 The first guide to diagnosis and treatment of gliomas in central nervous system in China was published, which emphasized the importance of standardized diagnosis and treatment of gliomas and multidisciplinary comprehensive treatment to prolong patients' lives. This comprehensive treatment mode needs the close cooperation of neurosurgery, radiotherapy and pathology.